Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. prostate implant
Show results for
Products

Companies

News
Downloads

Refine by
Date

  • Older

Prostate Implant Articles & Analysis

8 news found

Interim results of the Expander-1 Clinical Study

Interim results of the Expander-1 Clinical Study

The XFLO Expander System is designed to provide patients with immediate relief BPH-related symptoms (LUTS) by placing an expander implant in the prostatic urethra using a low-profile delivery catheter and a standard flexible cystoscope. ...

ByProdeon Medical, Inc.


Isoray’s Cesium-131 Featured in Presentations at American Brachytherapy Society’s Annual Conference

Isoray’s Cesium-131 Featured in Presentations at American Brachytherapy Society’s Annual Conference

A review of implant techniques examining variability and/or similarity of different sized prostates for each brachytherapist was undertaken. ...

ByTheragenics


Data presented at the American Urology Association annual conference

Data presented at the American Urology Association annual conference

The Urocross Expander System consists of two primary components: the Urocross Delivery System and the preloaded Urocross Expander Implant. The implant is made of Nitinol and delivered to the prostatic urethra through the working channel of a flexible cystoscope. When deployed, the implant’s struts expand to place gentle and ...

ByProdeon Medical, Inc.


Promising Clinical Study Results of the Zenflow Spring System Featured at the AUA 2021 Meeting

Promising Clinical Study Results of the Zenflow Spring System Featured at the AUA 2021 Meeting

Study results from the Spring System from Zenflow, Inc., a medical device company developing a minimally invasive treatment for urinary obstruction caused by enlarged prostate, or benign prostatic hyperplasia (BPH), were featured at the American Urological Association 2021 annual meeting. ...

ByZenflow, Inc.


C4 Imaging Announces Sirius Positive Signal MRI Marker Given FDA 510(k) Clearance for Use with Isoray’s Cesium-131 Brachytherapy Seeds to Treat Prostate Cancer

C4 Imaging Announces Sirius Positive Signal MRI Marker Given FDA 510(k) Clearance for Use with Isoray’s Cesium-131 Brachytherapy Seeds to Treat Prostate Cancer

Food and Drug Administration (FDA) 510(k) clearance for the use of C4 Imaging’s Sirius positive-signal MRI (Magnetic Resonance Imaging) Markers with Isoray’s Cesium-131, brachytherapy seeds. Sirius is implanted during the treatment of prostate cancer with brachytherapy and is used to facilitate brachytherapy seed localization within the ...

ByTheragenics


C4 Imaging Announces Sirius Positive Signal MRI Marker Given FDA 510(k) Clearance for Use with Isoray’s Cesium-131 Brachytherapy Seeds to Treat Prostate Cancer

C4 Imaging Announces Sirius Positive Signal MRI Marker Given FDA 510(k) Clearance for Use with Isoray’s Cesium-131 Brachytherapy Seeds to Treat Prostate Cancer

Food and Drug Administration (FDA) 510(k) clearance for the use of C4 Imaging’s Sirius positive-signal MRI (Magnetic Resonance Imaging) Markers with Isoray’s Cesium-131, brachytherapy seeds. Sirius is implanted during the treatment of prostate cancer with brachytherapy and is used to facilitate brachytherapy seed localization within the ...

ByC4 Imaging LLC


C4 Imaging Announces an Additional FDA 510(k) Clearance for its Positive-Signal MRI Marker - Sirius

C4 Imaging Announces an Additional FDA 510(k) Clearance for its Positive-Signal MRI Marker - Sirius

Previously only gamma sterilization was available; the addition of ethylene oxide as an option increases convenience for customers and allows the benefits of MRI assisted brachytherapy with Sirius, also known as MRI assisted radiosurgery or MARS, to be made available to more prostate cancer patients. Brachytherapy, or radioactive seed implantation is a ...

ByC4 Imaging LLC


Cancer Targeted Technology Commences Second Phase of a $2.3M Contract to Develop an Innovative PSMA-targeted Radionuclide Therapy for Prostate Cancer

Cancer Targeted Technology Commences Second Phase of a $2.3M Contract to Develop an Innovative PSMA-targeted Radionuclide Therapy for Prostate Cancer

PSMA is over-expressed on prostate cancer and expression increases as the cancer metastasizes and becomes castrate-resistant. ...

ByCancer Targeted Technology

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical Equipment & Supplies
  • Medical Software
  • Medical Training Courses
  • Medical Industry Services
  • Medical Product Applications

Latest

  • Medical Industry News
  • Medical Industry Events

Publications

  • Medical Industry Articles & Case Studies
  • Medical Industry Books and Publications
  • Medical Industry Journals and Magazines
  • Medical Industry Downloads
  • Medical Industry Videos

Companies

  • Medical Industry Suppliers & Manufacturers

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT